[Effect of tyrosine-kinase Inhibitor on p15 gene transfected K562 cells]

Wei Wang1, Bing-Zhong Sun, Hong Xie

  • 1Department of Hematology, 175th Hospital of PLA, Zhangzhou 363000, China.

Insights

The study found that combining imatinib with p15 gene expression synergistically inhibits chronic myeloid leukemia (CML) cell proliferation and promotes apoptosis in K562 cells. Restoring p15 gene function significantly impacts CML cell behavior.

Area of Science:

  • Molecular Biology
  • Oncology
  • Genetics

Context:

  • Chronic myeloid leukemia (CML) is characterized by specific genetic mutations.
  • The p15 gene plays a role in cell cycle regulation and tumor suppression.
  • K562 cell line is a common model for CML research.

Purpose:

  • To investigate the combined therapeutic effect of imatinib and p15 gene expression on K562 cells.
  • To analyze the impact on cell proliferation, cell cycle, and apoptosis.
  • To determine if restoring p15 gene function enhances imatinib's efficacy.

Summary:

  • p15 gene deletion was confirmed in K562 cells, leading to loss of P15 protein function.
  • Stable expression of p15 gene in K562 cells inhibited proliferation and induced G0/G1 cell cycle arrest.
  • Combined treatment with imatinib and p15 gene expression significantly increased apoptosis and decreased survival rate.

Impact:

  • The findings suggest a synergistic effect between imatinib and p15 gene expression in CML treatment.
  • Restoring p15 gene function could be a potential strategy to enhance imatinib therapy for CML.
  • This research provides insights into novel therapeutic approaches for CML.